Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
enGene Therapeutics Inc. (ENGN) has three reporting persons—Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd.—each reporting shared beneficial ownership of 6,217,464 Common Shares, or 8.9%. The amount assumes exercise of 2,735,295 pre-funded warrants and is based on 67,016,316 Common Shares outstanding as of September 2, 2026.
The Master Fund directly holds 3,482,169 Common Shares and 2,735,295 pre-funded warrants, exercisable at $0.0001 per share subject to a 9.99% beneficial-ownership limit. The statement says the limit permits exercise of all the warrants as of September 30, 2026; Perceptive Advisors and Joseph Edelman do not directly hold Common Shares or pre-funded warrants.
Key Figures
Shared beneficial ownership:6,217,464 Common SharesPercentage of class:8.9%Common Shares outstanding:67,016,316 Common Shares+4 more
7 metrics
Shared beneficial ownership6,217,464 Common SharesReported by each of the three reporting persons; amount assumes exercise of pre-funded warrants
Percentage of class8.9%Reported by each reporting person
Common Shares outstanding67,016,316 Common SharesAs of September 2, 2026; basis for reported ownership percentages
Common Shares directly held3,482,169 Common SharesHeld directly by Perceptive Life Sciences Master Fund, Ltd.
Pre-funded warrants2,735,295 warrantsHeld directly by Perceptive Life Sciences Master Fund, Ltd.; immediately exercisable for Common Shares, subject to the Beneficial Ownership Limitation
Warrant exercise price$0.0001 per shareExercise price for the pre-funded warrants
Beneficial Ownership Limitation9.99%Limit on beneficial ownership following warrant exercise
"2,735,295 Pre-Funded Warrants held by the Reporting Persons"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Limitationregulatory
"subject to the Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared voting powertechnical
"Shared power to vote or to direct the vote"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powertechnical
"Shared power to dispose or to direct the disposition"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much ENGN beneficial ownership did the reporting persons report?
Each of Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. reported shared beneficial ownership of 6,217,464 Common Shares, or 8.9%. The same shared amount is reported for each; it is not three separate holdings to add together.
What are the terms of ENGN's pre-funded warrants held by the Master Fund?
The Master Fund directly holds 2,735,295 pre-funded warrants, immediately exercisable for Common Shares at $0.0001 per share, subject to a 9.99% Beneficial Ownership Limitation. As of September 30, 2026, the limitation permitted exercise of all the warrants.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
enGene Therapeutics Inc.
(Name of Issuer)
Common Shares
(Title of Class of Securities)
29286X101
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29286X101
1
Names of Reporting Persons
Perceptive Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,217,464.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,217,464.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,217,464.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.9 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
29286X101
1
Names of Reporting Persons
Joseph Edelman
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,217,464.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,217,464.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,217,464.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
29286X101
1
Names of Reporting Persons
Perceptive Life Sciences Master Fund, Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,217,464.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,217,464.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,217,464.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
enGene Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
4868 Rue Levy, Suite 220, Saint-Laurent, QC, Canada H4R 2P1
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to the Common Shares (the "Common Shares") of enGene Therapeutics Inc. (the "Issuer") are:
Perceptive Advisors LLC ("Perceptive Advisors")
Joseph Edelman ("Mr. Edelman")
Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
(c)
Citizenship:
Perceptive Advisors is a Delaware limited liability company.
Mr. Edelman is a United States citizen.
The Master Fund is a Cayman Islands corporation.
(d)
Title of class of securities:
Common Shares
(e)
CUSIP No.:
29286X101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 67,016,316 Common Shares outstanding as of September 2, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 8, 2026, and assume the exercise of pre-funded warrants (the "Pre-Funded Warrants") held by the Reporting Persons for 2,735,295 Common Shares.
Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Shares or Pre-Funded Warrants. The Master Fund directly holds 3,482,169 Common Shares and 2,735,295 Pre-Funded Warrants immediately exercisable for Common Shares at an exercise price of $0.0001 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Pre-Funded Warrants provide that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the Common Shares then issued and outstanding (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise all of their Pre-Funded Warrants. Perceptive Advisors serves as the investment manager of the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
(b)
Percent of class:
Perceptive Advisors: 8.9%
Mr. Edelman: 8.9%
Master Fund: 8.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0
(ii) Shared power to vote or to direct the vote:
Perceptive Advisors: 6,217,464
Mr. Edelman: 6,217,464
Master Fund: 6,217,464
(iii) Sole power to dispose or to direct the disposition of:
Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0
(iv) Shared power to dispose or to direct the disposition of:
Perceptive Advisors: 6,217,464
Mr. Edelman: 6,217,464
Master Fund: 6,217,464
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.